NOVARTIS NEWSROOM (194 press releases)
Advanced Filtering & Sorting Options:
PRESS RELEASE -- 5, January 2022
(PRESS RELEASE) New York, NY, United States, 5-Jan-2022 — /EuropaWire/ — The Conference Forum announced the launch of the 6th annual EU Patients as Partners in Medicines Development conference to take place virtually on January 24-25th, 2022 GMT time. This …
Read the full press release →PRESS RELEASE -- 13, September 2021
(PRESS RELEASE) AMERSFOORT, 13-Sep-2021 — /EuropaWire/ — Nutreco, a global leader in animal nutrition and aquafeed, has announced the appointment of Paul Bestford as the company’s new Chief Procurement Officer (CPO). Paul is coming from Burberry where he led the …
Read the full press release →PRESS RELEASE -- 22, March 2021
(PRESS RELEASE) BASEL, 22-Mar-2021 — /EuropaWire/ — Swiss multinational pharmaceutical Novartis appoints Karen L. Hale as Chief Legal Officer. She succeeds Shannon Klinger. Karen will be based in Basel, Switzerland and will join the Executive Committee of Novartis (ECN) and …
Read the full press release →PRESS RELEASE -- 19, January 2021
Project Africa GRADIENT calls on local researchers to submit proposals exploring the link between genetic diversity and response to malaria and tuberculosis drugs in African patients. Combined funding commitment of GBP 2.8 million (USD 3.6 million) over five years. Researchers …
Read the full press release →PRESS RELEASE -- 19, November 2020
The energy will be generated by the 179.9 MW TICO Wind Farm, located in the Spanish province of Zaragoza, Enel Green Power will be a “Green Enabler” for Novartis, supporting the company along its environmental sustainability journey (PRESS RELEASE) ROME, …
Read the full press release →PRESS RELEASE -- 5, October 2020
In a post-hoc analysis of HAWK and HARRIER, fewer Beovu (brolucizumab) patients had early persistent fluid (12.5% vs. 20.4% of aflibercept patients), defined as the presence of intra-retinal fluid and/or sub-retinal fluid through week 12 of treatment1 Patients with early persistent fluid treated with Beovu experienced greater …
Read the full press release →PRESS RELEASE -- 2, September 2020
Zurich accelerates development of digital services, creating a new unit to attract additional customers and meet their rapidly changing needs Jack Howell, CEO Asia Pacific (APAC), to lead the new Global Business Platforms unit focusing on digital services Ericson Chan, …
Read the full press release →PRESS RELEASE -- 6, January 2020
(PRESS RELEASE) BASEL, 6-Jan-2020 — /EuropaWire/ — ChemChina and Sinochem announce the creation of Syngenta Group. The new holding company is the consolidation of both companies’ agricultural assets. Mark Patrick, Chief Financial Officer (CFO) and member of the Syngenta Executive …
Read the full press release →PRESS RELEASE -- 22, August 2019
The initiative aims at transforming the way companies are valued (PRESS RELEASE) FRANKFURT AM MAIN, 22-Aug-2019 — /EuropaWire/ — Deutsche Bank has announced it is joining the value balancing alliance e.V.. Established as a non-profit organization the alliance was founded …
Read the full press release →PRESS RELEASE -- 15, March 2019
(PRESS RELEASE) BASEL, 15-Mar-2019 — /EuropaWire/ — Sandoz’s current Region Head Europe Francesco Balestrieri has just been appointed ad-interim CEO of Sandoz reporting directly to Vas Narasimhan, CEO, Novartis. The change is made as the current CEO of Sandoz, a …
Read the full press release →PRESS RELEASE -- 31, January 2019
(PRESS RELEASE) MARTORELL, 31-Jan-2019 — /EuropaWire/ — SEAT’s recognition as a Top Employer in Spain consolidates the company’s commitment to the professional development of its more than 15,000 employees. Top Employer has given the car maker its seal of approval for …
Read the full press release →PRESS RELEASE -- 4, December 2018
Sandoz has been certified by the Top Employers Institute for its exceptional employee offerings in Asia Pacific (APAC) The annual, international research undertaken by the Top Employers Institute recognizes leading employers around the world This exclusive certification underlines Sandoz´ commitment …
Read the full press release →PRESS RELEASE -- 30, October 2018
Agreement includes a clinical trial to evaluate a combination of tropifexor (LJN452) and one or more Pfizer compounds for the treatment of non-alcoholic steatohepatitis (NASH) Novartis has a leading development portfolio in non-viral liver diseases, including NASH There are currently no …
Read the full press release →PRESS RELEASE -- 24, October 2018
Alcon SMART Suite, powered by Philips’ HealthSuite digital platform, aims to drive innovation in ophthalmology delivering personalized and seamless end-to-end care for cataract patients AMSTERDAM, 24-Oct-2018 — /EuropaWire/ — Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, …
Read the full press release →PRESS RELEASE -- 13, September 2018
Goldschmidt: “I look forward to working with the highly experienced team at STADA and continuing the Group’s long-term growth” Supervisory Board Chairman von Au: “Goldschmidt is the right man that STADA needs to ensure the Group successfully retains its strong …
Read the full press release →PRESS RELEASE -- 31, August 2018
Approval based on COMBI-AD study demonstrating greater than 50% reduction in risk of disease recurrence or death in stage III melanoma patients More than 50% of stage III melanoma patients are likely to recur to stage IV during their lifetime …
Read the full press release →PRESS RELEASE -- 31, August 2018
Decision based on five-year data from COMPASS-XT long-term safety study Alcon advises ophthalmic surgeons to cease further implantation BASEL, 31-Aug-2018 — /EuropaWire/ — Reflecting its uncompromising commitment to patient safety, Alcon today announced an immediate, voluntary market withdrawal of the CyPass Micro-Stent from …
Read the full press release →PRESS RELEASE -- 30, August 2018
The EC approval is based on the first global CAR-T registration trials, which included patients from eight European countries and demonstrated durable responses and a consistent safety profile in r/r pediatric B-cell ALL and r/rDLBCL Novartis is the only company with an approved …
Read the full press release →PRESS RELEASE -- 24, August 2018
SOLAR-1 evaluated BYL719 plus fulvestrant vs. fulvestrant alone in HR+/HER2- advanced breast cancer patients with PIK3CA mutations who progressed on or following treatment with an aromatase inhibitor with or without a CDK4/6 inhibitor[1] Approximately 40% of HR+ advanced breast cancer …
Read the full press release →PRESS RELEASE -- 25, July 2018
Novartis extends agreement with the WHO for the donation of Egaten® for the treatment of liver fluke, a neglected tropical disease, also known as fascioliasis, that infects more than 2.4 million people globally[1] Since the start of the donation program in …
Read the full press release →